دورية أكاديمية
Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents
| العنوان: | Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents |
|---|---|
| المؤلفون: | Sahaja Acharya, MD, Mustafaa Mahmood, BS, Daniel Mullen, DDS, MS, Deshan Yang, PhD, Christina I. Tsien, MD, Jiayi Huang, MD, Stephanie M. Perkins, MD, Keith Rich, MD, Michael Chicoine, MD, Eric Leuthardt, MD, Joshua Dowling, MD, Gavin Dunn, MD, PhD, Jesse Keller, MD, Clifford G. Robinson, MD, Christopher Abraham, MD |
| المصدر: | Advances in Radiation Oncology, Vol 2, Iss 4, Pp 572-580 (2017) |
| بيانات النشر: | Elsevier, 2017. |
| سنة النشر: | 2017 |
| المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Purpose: Stereotactic radiosurgery (SRS) in combination with immunotherapy (IMT) or targeted therapy is increasingly being used in the setting of melanoma brain metastases (MBMs). The synergistic properties of combination therapy are not well understood. We compared the distant intracranial failure rates of intact MBMs treated with SRS, SRS + IMT, and SRS + targeted therapy. Methods and materials: Combination therapy was defined as delivery of SRS within 3 months of IMT (anti-CTLA-4 /anti-PD-1 therapy) or targeted therapy (BRAF/MEK inhibitors). The primary endpoint was distant intracranial failure after SRS, which was defined as any new MBM identified on brain magnetic resonance imaging. Outcomes were evaluated using the Kaplan Meier method and Cox proportional hazards. Results: A total of 72 patients with melanoma with 233 MBMs were treated between April 2006 and April 2016. The number of MBMs within each treatment group was as follows: SRS: 121; SRS + IMT: 48; and SRS + targeted therapy: 64. The median follow-up was 8.9 months. One-year distant intracranial control rates for SRS, SRS + IMT, and SRS + targeted therapy were 11.5%, 60%, and 10%, respectively (P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2452-1094 |
| العلاقة: | http://www.sciencedirect.com/science/article/pii/S2452109417301082Test; https://doaj.org/toc/2452-1094Test |
| DOI: | 10.1016/j.adro.2017.07.003 |
| الوصول الحر: | https://doaj.org/article/263aea1684d249dc8f440ca130c8b6eaTest |
| رقم الانضمام: | edsdoj.263aea1684d249dc8f440ca130c8b6ea |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24521094 |
|---|---|
| DOI: | 10.1016/j.adro.2017.07.003 |